110 related articles for article (PubMed ID: 23527524)
1. Reversing multidrug resistance (MDR1, ABCB1) in acute myeloid leukemia: back to the ABCs.
Rund D
Leuk Lymphoma; 2013 Nov; 54(11):2347-8. PubMed ID: 23527524
[No Abstract] [Full Text] [Related]
2. Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.
Chen TL; Estey EH; Othus M; Gardner KM; Markle LJ; Walter RB
Leuk Lymphoma; 2013 Nov; 54(11):2534-6. PubMed ID: 23432687
[No Abstract] [Full Text] [Related]
3. Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia.
Pallis M; Russell N
Leukemia; 2004 Dec; 18(12):1927-30. PubMed ID: 15483678
[No Abstract] [Full Text] [Related]
4. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Dahl GV; Lacayo NJ; Brophy N; Dunussi-Joannopoulos K; Weinstein HJ; Chang M; Sikic BI; Arceci RJ
J Clin Oncol; 2000 May; 18(9):1867-75. PubMed ID: 10784627
[TBL] [Abstract][Full Text] [Related]
5. [A clinical study on multidrug resistance gene (MDR1) expression in acute leukemia].
Pu J; Liu H; Lou F
Zhonghua Nei Ke Za Zhi; 1995 Oct; 34(10):655-8. PubMed ID: 8731823
[TBL] [Abstract][Full Text] [Related]
6. Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy.
Chauhan PS; Bhushan B; Singh LC; Mishra AK; Saluja S; Mittal V; Gupta DK; Kapur S
Exp Mol Pathol; 2012 Feb; 92(1):44-9. PubMed ID: 22037714
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia.
Li GY; Liu JZ; Zhang B; Wang LX; Wang CB; Chen SG
Biomed Pharmacother; 2009 Sep; 63(8):566-70. PubMed ID: 19095404
[TBL] [Abstract][Full Text] [Related]
8. [The causes of treatment ineffectiveness in acute myelogenous leukemia--the role of blast resistance to cytotoxic drugs].
Machaczka M; Rucińska M; Jabłoński M; Skotnicki AB
Przegl Lek; 1998; 55(7-8):407-13. PubMed ID: 10021886
[TBL] [Abstract][Full Text] [Related]
9. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
List AF
Leukemia; 1996 Jun; 10(6):937-42. PubMed ID: 8667648
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Kornblau SM; Estey E; Madden T; Tran HT; Zhao S; Consoli U; Snell V; Sanchez-Williams G; Kantarjian H; Keating M; Newman RA; Andreeff M
J Clin Oncol; 1997 May; 15(5):1796-802. PubMed ID: 9164187
[TBL] [Abstract][Full Text] [Related]
11. Expression of three different ATP-binding cassette transporters and correlation to chemoresistance in acute myeloid leukemia.
Palaiologou D; Panayiotidis P; Papanikolaou G; Georgiou G; Boutsikas G; Hatzinicolaou SL; Pangalis GA; Sakellaropoulos N; Vassilakopoulos TP; Angelopoulou MK
Int J Lab Hematol; 2015 Feb; 37(1):e7-e10. PubMed ID: 24809224
[No Abstract] [Full Text] [Related]
12. Facts about FCE (fludarabine, cytarabine, etoposide) in acute myeloid leukemia.
Medeiros BC
Acta Haematol; 2014; 131(4):200-1. PubMed ID: 24296429
[No Abstract] [Full Text] [Related]
13. Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.
Fleming S; Ong DM; Jackson K; Avery S; Mollee P; Marlton P; Kennedy G; Wei AH
Br J Haematol; 2017 Apr; 177(2):328-330. PubMed ID: 27029236
[No Abstract] [Full Text] [Related]
14. Analysis of MDR1 and MDR3 multidrug resistance gene expression and amplification in consecutive samples in patients with acute leukaemias.
MacFarland A; Dawson AA; Pearson CK
Leuk Lymphoma; 1995 Sep; 19(1-2):135-40. PubMed ID: 8574159
[TBL] [Abstract][Full Text] [Related]
15. Assessment of drug resistance in acute myeloid leukemia.
Funato T; Harigae H; Abe S; Sasaki T
Expert Rev Mol Diagn; 2004 Sep; 4(5):705-13. PubMed ID: 15347263
[TBL] [Abstract][Full Text] [Related]
16. Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia.
Marin JJ; Briz O; Rodríguez-Macias G; Díez-Martín JL; Macias RI
Blood Rev; 2016 Jan; 30(1):55-64. PubMed ID: 26321049
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.
Lancet JE; Baer MR; Duran GE; List AF; Fielding R; Marcelletti JF; Multani PS; Sikic BI
Leuk Res; 2009 Aug; 33(8):1055-61. PubMed ID: 19108889
[TBL] [Abstract][Full Text] [Related]
18. Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.
Filanovsky K; Shvidel L; Shtalrid M
J Clin Oncol; 2010 Mar; 28(7):e115-6; author reply e117-8. PubMed ID: 20100951
[No Abstract] [Full Text] [Related]
19. Minimally differentiated acute myeloid leukemia with t(12;22)(p13;q11) translocation showing primary multidrug resistance and expressing multiple multidrug-resistant proteins.
Chen S; Xue Y; Zhu X; Wu Y; Pan J
Acta Haematol; 2007; 118(1):38-41. PubMed ID: 17476096
[TBL] [Abstract][Full Text] [Related]
20. [Expression of MUC1 gene and MDR1 gene in non-M3 subtype acute leukemia and their correlations to clinical treatment efficacy].
Li GW; Wang DN; Lin DJ; Li XD; Lin GZ; He Y; Lin Q; Huang RW
Ai Zheng; 2005 Aug; 24(8):1011-4. PubMed ID: 16086884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
